SARS-CoV-2 Spike Glycoprotein
SARS-CoV-2 | SARS-Cov2 | COVID-19 | SARS-CoV2 (COVID-19) Spike
Coronavirus SARS-CoV, Coronavirus SARS-CoV-2
(tested or 100% immunogen sequence identity)
The monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
LS-C829136 is a rabbit IgG kappa recombinant form of a human IgG1 monoclonal antibody generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV (B-cell clone CR3022). This antibody binds to amino acids 318-510 in the S1 domain of the SARS-CoV and SARS-CoV-2 (COVID-19) Spike protein, as well as the P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein. Detailed information about antibody binding can be found in these publications: (SARS-CoV-2) Tian X et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020 Feb 17;9(1):382-385. PMID: 32065055(SARS-CoV) ter Meulen et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants PLoS Med. 2006 Jul; 3(7): e237 PMID:16796401.An alternate human IgG kappa recombinant version of this antibody is also available as LS-C829135.
PBS, 0.02% ProClin™ 300.
Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
For research use only. Intended for use by laboratory professionals.
This antibody carries the LSBio 100% Guarantee.
About SARS-CoV-2 Spike Glycoprotein